In situ modulation of oxidative stress: A novel and efficient strategy to kill cancer cells

Current Medicinal Chemistry

Volumn 16, Issue 15, 2009, Pages 1821-1830

  Verrax, J ^a   Pedrosa, R Curi ^b   Beck, R ^a   Dejeans, N ^a   Taper, H ^a   Calderon, Pedro Buc ^a,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c NONE   (Belgium)

Author keywords

Antioxidant enzymes; Ascorbate; Glycolysis; Hepatoma; Menadione redox cycling; Vitamin C uptake

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ASCORBIC ACID; CATALASE; DEHYDROASCORBIC ACID; GLUCOSE TRANSPORTER 1; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HEXOKINASE; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1; LACTIC ACID; MENADIONE; MITOCHONDRIAL ENZYME; NAPHTHOQUINONE; PHYTOMENADIONE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CELL DESTRUCTION; CELL DEATH; CELL HYPOXIA; CELL KILLING; CELL STRESS; CELL SURVIVAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA FRAGMENTATION; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG DESIGN; DRUG POTENTIATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; GLUCOSE INTAKE; GLYCOLYSIS; HEPATOMA CELL; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; VITAMIN METABOLISM;

ANIMALS; CELL LINE, TUMOR; HUMANS; MICE; NEOPLASMS; OXIDATIVE STRESS;

EID: 68449092620     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788186057     Document Type: Review

References (79)

1. Boerner, J.L.; Biscardi, J.S.; Parsons, S.J. Overview of Oncogenesis. In The cancer handbook. M.R. Alison, Ed.; Nature Publishing Group: London, 2002, pp. 25-34.
2. Peinado, M.A.; Malkhosyan, S.; Velazquez, A.; Perucho, M. Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 1992, 89, 10065-10069.
3. Kerangueven, F.; Noguchi, T.; Coulier, F.; Allione, F.; Wargniez, V.; Simony-Lafontaine, J.; Longy, M.; Jacquemier, J.; Sobol, H.; Eisinger, F.; Birnbaum, D. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res., 1997, 57, 5469-5474.
4. Cahill, D.P.; Kinzler, K.W.; Vogelstein, B.; Lengauer, C. Genetic instability and darwinian selection in tumours. Trends Cell Biol., 1999, 9, 57-60.
5. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 7-70.
6. Kendall, S.D.; Linardic, C.M.; Adam, S.J.; Counter, C.M. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res., 2005, 65, 9824-9828.
7. Verrax, J.; Vanbever, S.; Stockis, J.; Taper, H.; Buc Calderon, P. Role of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cells. Int. J. Cancer, 2007, 120, 1192-1197.
8. Warburg, O. On the origin of cancer cells. Science, 1956, 123, 309-314.
9. Cuezva, J.M.; Krajewska, M.; de Heredia, M.L.; Krajewski, S.; Santamaria, G.; Kim, H.; Zapata, J.M.; Marusawa, H.; Chamorro, M.; Reed, J.C. The bioenergetic signature of cancer: A marker of tumor progression. Cancer Res., 2002, 62, 6674-6681.
10. Bresnick, E. Biochemistry of Cancer. In Cancer medicine 4th Edition. J.F. Holland, R.C. Bast, D.L. Morton, E. Frei, D.W. Kufe, R.R. Weichselbaum, Eds.; Williams and Wilkins: Baltimore, 1997, pp. 143-163.
11. Brown, J.M. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol. Med. Today, 2000, 6, 157-162.
12. Kimura, H.; Braun, R.D.; Ong, E.T.; Hsu, R.; Secomb, T.W.; Papahadjopoulos, D.; Hong, K.; Dewhirst, M.W. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res., 1996, 56, 5522-5528.
13. McBride, W.H.; Dougherty, G.J.; Milas, L. Molecular Mechanisms of Radiotherapy. In The cancer handbook, M.R. Alison, Ed.; Nature Publishing Group: London, 2002, pp. 1359-1370.
14. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003, 3, 721-732.
15. Agus, D.B.; Vera, J.C.; Golde, D.W. Stromal cell oxidation: A mechanism by which tumors obtain vitamin C. Cancer Res., 1999, 59, 4555-4558.
16. Macheda, M.L.; Rogers, S.; Best, J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol., 2005, 202, 654-662.
17. Goel, A.; Mathupala, S.P.; Pedersen, P.L. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J. Biol. Chem., 2003, 278, 15333-15340.
18. Isidoro, A.; Martinez, M.; Fernandez, P.L.; Ortega, A.D.; Santamaria, G.; Chamorro, M.; Reed, J.C.; Cuezva, J.M. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem. J., 2004, 378, 17-20.
19. Nishikawa, M.; Oshitani, N.; Matsumoto, T.; Nishigami, T.; Arakawa, T.; Inoue, M. Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. Br. J. Cancer, 2005, 93, 331-337.
20. Birch-Machin, M.A. Using mitochondrial DNA as a biosensor of early cancer development. Br. J. Cancer, 2005, 93, 271-272.
21. Gatenby, R.A.; Gawlinski, E.T. The glycolytic phenotype in carcinogenesis and tumor invasion: Insights through mathematical models. Cancer Res., 2003, 63, 3847-3854.
22. Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4, 891-899
23. Gatenby, R.A.; Gawlinski, E.T.; Gmitro, A.F.; Kaylor, B.; Gillies, R.J. Acid-mediated tumor invasion: A multidisciplinary study. Cancer Res., 2006, 66, 5216-5223.
24. Frieboes, H.B.; Zheng, X.; Sun, C.H.; Tromberg, B.; Gatenby, R.; Cristini, V. An integrated computational/experimental model of tumor invasion. Cancer Res., 2006, 66, 1597-1604.
25. Gatenby, R.A., Gillies, R.J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer, 2008, 8, 56-61
26. Zu, X.L.; Guppy, M. Cancer metabolism: Facts, fantasy, and fiction. Biochem. Biophys. Res. Commun., 2004, 313, 459-465
27. Xu, R.H.; Pelicano, H.; Zhou, Y.; Carew, J.S.; Feng, L.; Bhalla, K.N.; Keating, M.J.; Huang, P. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res., 2005, 65, 613-621.
28. Zhu, Z.; Jiang, W.; McGinley, J.N.; Thompson, H.J. 2-Deoxyglucose as an energy restriction mimetic agent: Effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res., 2005, 65, 7023-7030.
29. Banhegyi, G.; Braun, L.; Csala, M.; Puskas, F.; Mandl, J. Ascorbate metabolism and its regulation in animals. Free Rad. Biol. Med., 1997, 23, 793-803.
30. Daruwala, R.; Song, J.; Koh, W.S.; Rumsey, S.C.; Levine, M. Cloning and functional characterization of the human sodiumdependent vitamin C transporters hSVCT1 and hSVCT2. FEBS Lett., 1999, 460, 480-484.
31. Tsukaguchi, H.; Tokui, T.; Mackenzie, B.; Berger, U.V.; Chen, X.Z.; Wang, Y.; Brubaker, R.F.; Hediger, M.A. A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature, 1999, 399, 70-75.
32. Takanaga, H.; Mackenzie, B.; Hediger, M.A. Sodium-dependent ascorbic acid transporter family SLC23. Pflugers Arch.-Eur. J. Physiol., 2004, 447, 677-682.
33. Vera, J.C. Rivas, C.I.; Fischbarg, J.; Golde, D.W. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature, 1993, 364, 79-82
34. Birnbaum, M.J.; Haspel, H.C.; Rosen, O.M. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science, 1987, 235, 1495-1498.
35. Park, J.B.; Levine, M. Purification, cloning and expression of dehydroascorbic acid-reducing activity from human neutrophils: identification as glutaredoxin. Biochem. J., 1996, 315, 931-938.
36. Vera, J.C.; Rivas, C.I.; Zhang, R.H.; Farber, C.M.; Golde, D.W. Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid. Blood, 1994, 84, 1628-1634.
37. Langemann, H.; Torhorst, J.; Kabiersch, A.; Krenger, W.; Honegger, C.G. Quantitative determination of water- and lipid-soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int. J. Cancer, 1989, 43, 1169-1173.
38. Fiaschi, A.I.; Cozzolino, A.; Ruggiero, G.; Giorgi, G. Glutathione, ascorbic acid and antioxidant enzymes in the tumor tissue and blood of patients with oral squamous cell carcinoma. Eur. Rev. Med. Pharmacol. Sci., 2005, 9, 361-367.
39. Gon&alves, T.L.; Erthal, F.; Corte, C.L.; Muller, L.G.; Piovezan, C.M.; Nogueira, C.W.; Rocha J.B. Involvement of oxidative stress in the pre-malignant and malignant states of cervical cancer in women. Clin. Biochem., 2005, 38, 1071-1075.
40. Chen, Q.; Espey, M.G.; Sun, A.Y.; Lee, J.H.; Krishna, M.C.; Shacter, E.; Choyke, P.L.; Pooput, C.; Kirk, K.L.; Buettner, G.R.; Levine, M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular. fluid in vivo. Proc. Natl. Acad. Sci. USA., 2007, 104, 8749-8754
41. Verrax, J.; Buc Calderon, P. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Rad. Biol. Med., 2009, doi:10.1016/ j.freeradbiomed.2009.02.016.
42. Rumsey, S.C.; Kwon, O.; Xu, G.W.; Burant, C.F.; Simpson, I.; Levine, M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J. Biol. Chem., 1997, 272, 18982-18989.
43. Baader, S.L.; Bruchelt, G.; Trautner, M.C.; Boschert, H.; Niethammer, D. Uptake and cytotoxicity of ascorbic acid and dehydroascorbic acid in neuroblastoma (SK-N-SH) and neuroectodermal (SK-N-LO) cells). Anticancer Res., 1994, 14, 221-227.
44. Spielholz, C.; Golde, D.W.; Houghton, A.N.; Nualart, F.; Vera, J.C. Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. Cancer Res., 1997, 57, 2529-2537.
45. Pelicano, H.; Carney, D.; Huang, P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Update, 2004, 7, 97-110.
46. Vafa, O.; Wade, M.; Kern, S.; Beeche, M.; Pandita, T.K.; Hampton, G.M.; Wahl, G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell, 2002, 9, 1031-1044.
47. Matés, J.M. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology, 2000, 153, 83-104.
48. Burdon, R.H. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Rad. Biol. Med., 1995, 18, 775-794.
49. Borovic, S.; Cipak, A.; Meinitzer, A.; Kejla, Z.; Perovic, D.; Waeg, G.; Zarkovic, N. Differential sensitivity to 4-hydroxynonenal for normal and malignant mesenchymal cells. Redox Rep., 2007, 12, 50-54.
50. Trachootham, D.; Zhou, Y.; Zhang, H.; Demizu, Y.; Chen, Z.; Pelicano, H.; Chiao, P.J.; Achanta, G.; Arlinghaus, R.B.; Liu, J.; Huang, P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell, 2006, 10, 241-252.
51. Trachootham, D.; Zhang, H.; Zhang, W.; Feng, L.; Du, M.; Zhou, Y.; Chen, Z.; Pelicano, H.; Plunkett, W.; Wierda, W.G.; Keating, M.J.; Huang, P. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood, 2008, 112, 1912-1922.
52. Sun, Y.; Oberley, L.W.; Elwell, J.H.; Sierra-Rivera, E. Antioxidant enzyme activities in normal and transformed mouse liver cells. Int. J. Cancer, 1989, 44, 1028-1033.
53. Sun, Y.; Oberley, L.W.; Oberley, T.D.; Elwell, J.H.; Sierra-Rivera, E. Lowered antioxidant enzymes in spontaneously transformed embryonic mouse liver cells in culture. Carcinogenesis, 1993, 14, 1457-1463.
54. Coursin, D.B.; Cihla, H.P.; Sempf, J.; Oberley, T.D.; Oberley, L.W. An immunohistochemical analysis of antioxidant and glutathione S-transferase enzyme levels in normal and neoplastic human lung. Histol. Histopathol., 1996, 11, 851-860.
55. Baker, A.M.; Oberley, L.W.; Cohen, M.B. Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate, 1997, 32, 229-233.
56. Oberley, T.D.; Oberley, L.W. Antioxidant enzyme levels in cancer. Histol. Histopathol., 1997, 12, 525-535.
57. Jaruga, P.; Zastawny, T.H.; Skokowski, J.; Dizdaroglu, M.; Olinski, R. Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett., 1994, 341, 59-64.
58. Verrax, J.; Cadrobbi, J.; Marques, C.; Taper, H.; Habraken, Y.; Piette, J.; Buc Calderon, P. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis, 2004, 9, 223-233.
59. Yang, J.; Lam, E.W.; Hammad, H.M.; Oberley, T.D.; Oberley, L.W. Antioxidant enzyme levels in oral squamous cell carcinoma and normal human oral epithelium. J. Oral Pathol. Med., 2002, 31, 71-77.
60. Chung-man Ho, J.; Zheng, S.; Comhair, S.A.; Farver, C.; Erzurum, S.C. Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res., 2001, 61, 8578-8585
61. Svensk, A.M.; Soini, Y.; Pääkkö, P.; Hiravikoski, P.; Kinnula, V.L. Differential expression of superoxide dismutases in lung cancer. Am. J. Clin. Pathol., 2004, 122, 395-404
62. Powis, G.; Mustacich, D.; Coon, A. The role of the redox protein thioredoxin in cell growth and cancer. Free Rad. Biol. Med., 2000, 29, 312-322.
63. Taper, H.S.; de Gerlache, J.; Lans, M.; Roberfroid, M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int. J. Cancer, 1987, 40, 575-579
64. Taper, H.S.; Keyeux, A.; Roberfroid, M. Potentiation of radiotherapy by non-toxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res., 1996, 16, 499-503.
65. Taper, H.S.; Roberfroid, M. Non-toxic sensitization of cancer chemotherapy by combined vitamin C and K3 pretreatment in a mouse tumor resistant to oncovin. Anticancer Res., 1992, 12, 1651-1654.
66. Taper, H.S.; Jamison, J.M.; Gilloteaux, J.; Summers, J.L.; Buc Calderon, P. Inhibition of the development of metastases by dietary vitamin C:K3 combination. Life Sci., 2004, 75, 955-967.
67. Verrax, J.; Delvaux, M.; Beghein, N.; Taper, H.; Gallez, B.; Buc Calderon P. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Rad. Res., 2005, 39, 649-657.
68. Zhang, W.; Negoro, T.; Satoh, K.; Jiang, Y.; Hashimoto, K.; Kikuchi, H.; Nishikawa, H.; Miyata, T.; Yamamoto, Y., Nakano, K.; Yasumoto, E.; Nakayachi, T.; Mineno, K.; Satoh, T.; Sakagami, H. Synergistic cytotoxic action of vitamin C and vitamin K3. Anticancer Res., 2001, 21, 3439-3444.
69. Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M.; Boyle, P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 2007, 18, 581-592.
70. Chandra, J. Oxidative stress by targeted agents promotes cytotoxicity in hematological malignancies. Antioxid. Redox Signal, 2008, doi:10.1089/ARS.2008.2302.
71. Kumar, B.; Koul, S.; Khandrika, L.; Meacham, R.B.; Koul, H.K. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res., 2008, 68, 1777-1785.
72. Nogueira, V.; Park, Y.; Chen, C.C.; Xu, P.Z.; Chen, M.L.; Tonic, I.; Unterman, T.; Hay, N. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell, 2008, 14, 458-470.
73. Dasmahapatra, G.; Rahmani, M.; Dent, P.; Grant, S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood, 2006, 107, 232-240.
74. Chang, J.E.; Voorhees, P.M.; Kolesar, J.M.; Ahuja, H.G.; Sanchez, F.A.; Rodriguez, G.A.; Kim, K.; Werndli, J.; Bailey, H.H.; Kahl, B.S. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: A Wisconsin Oncology Network study. Hematol. Oncol., 2009, 27, 11-16.
75. Maeda, H.; Hori, S.; Ohizumi, H.; Segawa, T.; Kakehi, Y.; Ogawa, O.; Kakizuka, A. Effective treatment of advanced solid tumors by the bcombination of arsenic trioxide and l-buthionine-sulfoximine. Cell Death Differ., 2004, 11, 737-746.
76. Zhang, H.; Trachootham, D.; Lu, W.; Carew, J.; Giles, F.J.; Keating, M.J.; Arlinghaus, R.B.; Huang, P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia, 2008, 22, 1191-1199.
77. Lowry, O.H.; Rosebrough, N.J.; Farr, L.; Randall, R. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 1951, 193, 265-275.
78. Hissin, P.J.; R. Hilf. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal. Biochem., 1976, 74, 214-226.
79. Wrobleski, F.; Ladue, J. Lactic deshydrogenase activity in blood. Proc. Soc. Exp. Biol. Med., 1955, 90, 210-213.